- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01230411
Pilot Study to Collect and Evaluate Data on the Use of IV* Ibuprofen in the Treatment of an Acute Migraine Attack (intravenous)
A Double-blind, Placebo-controlled Pilot Study to Collect and Evaluate Data on the Use of Intravenous Ibuprofen in the Treatment of an Acute Migraine Attack
This is a pilot trial to collect data on the use of intravenous ibuprofen (IVIb) in the treatment of an acute migraine attack. Data will be collected on the efficacy of IVIb in subjects who are treated with study medication between 2 and 72 hours from time of onset of headache.
Periodic safety and efficacy assessments will be performed prior to and after study drug administration.
Null hypothesis: There is no difference in the proportion of subjects in the 2 treatment groups (active treatment and placebo) who have pain relief at 2 hours after the completion of the double-blind treatment infusion. Pain relief is defined as a reduction in headache pain level from severe or moderate decreased to mild or headache-free, respectively.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a 3 visit trial: screening visit, treatment visit, and final visit. Screening visit and a treatment visit may occur on the same day. Additionally, there will be one follow-up phone call at 24 hours post-dose. Subjects will be screened and the investigator will determine whether or not the subject experiences episodic migraine headaches. When a potential subject is seen as an office patient at the Jefferson Headache Center, has a headache, and is referred by the PI or co-investigator to this study, the referring study physician will document that the subject's cognition is intact and the subject is able to understand and sign the informed consent at that time. If the potential subject's cognition is affected by the migraine, the subject must return to the Jefferson Headache Center for the research screening visit when the headache and cognitive difficulties have resolved. Subjects who are not being seen as an office patient on the day of screening must be headache-free at the time of screening.
Those subjects who meet the qualifying criteria will be eligible for treatment in the study. Subjects who qualify will be asked to come to the Jefferson Headache Center within 2 to 72 hours following the onset of pain.
IVIb or placebo will be administered intravenously as the study treatment. For active treatment, 800 mg of injectable ibuprofen will be placed in 250 ml of normal saline, and infused over 7-10 minutes. (Infusion time may be increased up to 1 hour if necessary due to possible anatomical restrictions). The placebo group will receive 250 ml of normal saline, infused over 7-10 minutes. (Infusion time may be increased up to 1 hour if necessary due to possible anatomical restrictions). Safety and efficacy assessments will be made periodically just prior to and after administration of study drug. Migraine pain and associated symptom assessments will be measured by the subjects for 24 hours from the administration of study drug for the treated attack. If subjects still have a moderate to severe headache at 2 hours after receiving double-blind study drug, they will receive a rescue dose of 800 mg. IV Ibuprofen. Subjects will be discharged at 4 hours post study drug dose, or when clinically indicated.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Jefferson Headache Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects between the ages of 18 and 65, inclusive
- Subject diagnosed with episodic migraine, with or without aura according to ICHD-2 criteria for at least one-year prior to screening
- Subject experiences between 2-10 migraine attacks per month (during the previous 6 months) with no more than 15 days of headache per month.
- Subject is using or agrees to use for the duration of participation a medically acceptable form of contraception (as determined by investigator), if female and of child-bearing potential
- Subject is able to come for 4 hour in-clinic treatment of an acute migraine attack
- Subjects are able to understand and comply with all study procedures.
- Subject provides written informed consent prior to any screening procedures being conducted
- If subject is on an allowable migraine preventive medication, the dose has been stable for at least 4 weeks prior to screening and the dose will remain stable throughout study participation.
Exclusion Criteria:
- Unable to make a reliable self-report of pain intensity to pain relief
- Use of analgesic or opioid within 24 hours of onset of headache to be treated with study medication. (If subject has an eligible headache and has taken a triptan or DHE within 24 hours, but greater than 2 hours before study drug dosing, they can be treated with study medication.)
- Patients taking the following medications on a regular basis: warfarin, lithium, ACE-inhibitors, loop diuretics, thiazide diuretics, ARBs, and methotrexate.
- Patients with active, clinically significant anemia
- Patients with a history or evidence of asthma
- Patients with a history heart failure
- Subjects with severely impaired hepatic or renal function, as determined by the investigator
- Patients with a history of allergy or hypersensitivity to any component of IVIb, aspirin (or aspirin related products), NSAIDs, or COX-2 inhibitors
- Pregnant or nursing women
- Patients who have a history of congenital bleeding diathesis (e.g., hemophilia) or any active clinically significant bleeding, or have underlying platelet dysfunction including (but not limited to) idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, or congenital platelet dysfunction
- Patients who have GI bleeding that required medical intervention within the previous 6 weeks (unless definitive surgery has been performed.)
- Patients who have a platelet count less than 100,000, as determined within the 28 days prior to treatment
- Pre-existing or current dependence on opioids.
- Subjects who have participated in an investigational drug trial in the 30 days prior to the screening visit
- Subjects with uncontrolled hypertension
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
IV saline administration as placebo
|
250 cc of placebo administered IV
|
Experimental: Ibuprofen
IV ibuprofen
|
800 mg ibuprofen in 250 cc saline administered IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of Proportion of Subjects in Control and Active Treatment Groups Who Have Pain Relief at 2 Hours After the Completion of the Double-blind Treatment Infusion.
Time Frame: 2 hours
|
Comparison of proportion of subjects in each treatment group (active treatment and placebo) who have pain relief at 2 hours after the completion of the double-blind treatment infusion.
Pain relief is defined as a reduction in headache pain level from severe or moderate decreased to mild or headache-free, respectively.
|
2 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stephen D. Silberstein, M.D., Jefferson Headache Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Ibuprofen
Other Study ID Numbers
- SDS/IVIb/01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Episodic Migraine
-
Mayo ClinicRecruiting
-
Kuang Tien General HospitalRecruitingThe Effects of Vitamin D Plus Omega-3 Polyunsaturated Fatty Acids in Patients With Episodic MigraineEpisodic MigraineTaiwan
-
AbbVieEnrolling by invitationEpisodic MigraineUnited States, Canada, Denmark, Hungary, Italy, Poland, Puerto Rico, Spain, United Kingdom, Israel, Japan, Sweden
-
AmgenNovartisCompletedEpisodic MigraineBelgium, United States, Spain, Czechia, Finland, United Kingdom, Israel, Ireland, Netherlands, Argentina, Austria, France, Germany, Greece, Italy, Poland, Portugal, Slovakia
-
AllerganCompletedEpisodic MigraineUnited States, Australia, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Russian Federation, Spain, Sweden, United Kingdom
-
Dr. Reddy's Laboratories LimitedCompleted
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Click Therapeutics, Inc.Active, not recruitingMigraine | Headache | Headache, Migraine | Episodic MigraineUnited States
-
Click Therapeutics, Inc.Active, not recruitingMigraine | Headache | Headache, Migraine | Episodic MigraineUnited States
-
Brigham and Women's HospitalYale University; VA Connecticut Healthcare System; National Center for Complementary... and other collaboratorsNot yet recruitingEpisodic Migraine
Clinical Trials on saline placebo
-
Vanderbilt University Medical CenterActive, not recruitingPostural Tachycardia SyndromeUnited States
-
Children's Hospital Los AngelesThrasher Research Fund; UCSF Benioff Children's Hospital OaklandCompleted
-
University of OxfordUniversity of BirminghamTerminatedTuberculosisUnited Kingdom
-
University of Texas Southwestern Medical CenterCompletedAcute BronchiolitisUnited States
-
University of MichiganRadiological Society of North AmericaTerminated
-
GlycoMimetics IncorporatedCompletedSickle Cell Disease | Vaso-occlusive Crisis | Pain CrisisUnited States, Canada
-
AstraZenecaGynecologic Oncology Group Foundation; European Network for Gynaecological...RecruitingLocally Advanced Cervical CancerSpain, Denmark, Italy, Korea, Republic of, Japan, Peru, China, Brazil, Taiwan, United States, Canada, Turkey, India, Poland, Mexico, Puerto Rico, Norway
-
University of CincinnatiUnited States Department of DefenseRecruitingMeniscus TearUnited States
-
Indiana Hand to Shoulder CenterCTM BiomedicalEnrolling by invitationOsteoarthritis | Osteoarthritis Thumb Base Joint | Carpometacarpal Osteoarthritis | ThumbUnited States
-
Dr. med. Mahir KarakasCompleted